Phase II Trial of Carboplatin, 5-FU and Cetuximab in Elderly Fit (no Frailty) Patients With Recurrent/Metastatic HNSCC

PHASE2CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

April 30, 2020

Study Completion Date

May 26, 2020

Conditions
Metastatic or Recurrent Head and Neck Squamous Cell Cancer
Interventions
DRUG

Carbo, 5FU, Cetuximab

"6 cycles (1 cycle = 21 days) of: carboplatin AUC 5, 5FU D1-4 1000mg/m²/d, every 21 days cetuximab weekly (400 mg/m² the first week of treatment and then 250 mg/m²/w)~Maintenance by cetuximab 500 mg/m² every 2 weeks until progression or toxicity"

Trial Locations (2)

83300

Hôpital de la Dracénie, Draguignan

94805

Institut Gustave Roussy, Villejuif

All Listed Sponsors
collaborator

Gustave Roussy, Cancer Campus, Grand Paris

OTHER

lead

Groupe Oncologie Radiotherapie Tete et Cou

OTHER

NCT01864772 - Phase II Trial of Carboplatin, 5-FU and Cetuximab in Elderly Fit (no Frailty) Patients With Recurrent/Metastatic HNSCC | Biotech Hunter | Biotech Hunter